Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.

person Deirdre J. Cohen Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY info_outline Deirdre J. Cohen, Judith D. Goldberg, Lawrence P. Leichman, Tsivia Hochman, Elliot Newman, Kevin Lee Du, Alec Megibow, Paul Eliezer Oberstein, Raed Moh'd Taiseer Al-Rajabi, Aaron J. Scott, Tanios S. Bekaii-Saab, Wells A. Messersmith, Colin D. Weekes

Authors person Deirdre J. Cohen Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY info_outline Deirdre J. Cohen, Judith D. Goldberg, Lawrence P. Leichman, Tsivia Hochman, Elliot Newman, Kevin Lee Du, Alec Megibow, Paul Eliezer Oberstein, Raed Moh'd Taiseer Al-Rajabi, Aaron J. Scott, Tanios S. Bekaii-Saab, Wells A. Messersmith, Colin D. Weekes Organizations Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, New York University, Grossman School of Medicine, New York, NY, New York University School of Medicine, New York, NY, Perlmutter Cancer Center, NYU Langone Health, New York, NY, Northwell Health, New York, NY, Yale Cancer Center, New Haven, CT, New York University, School of Medicine, New York, NY, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS, The University of Arizona, Tucson, AZ, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, University of Colorado, Aurora, CO, Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA Abstract Disclosures Research Funding No funding sources reported Background: Patients (pts) with pancreatic adenocarcinoma (PDAC) who are candidates for surgery are anatomically segregated into two groups: those with resectable tumors (R-PDAC), and those with borderline resectable tumors (BR-PDAC). For each group, complete surgical resection with no visible or microscopic disease left behind (R0 resection) is generally accepted as the path to cure. Neoadjuvant therapy (NAT) has been used to improve the R0 resection rate. However, the optimal role and type of NAT that will improve R0 resection rate and overall survival (OS) remains controversial. The Academic Gastrointestinal Cancer Consortium (AGICC) evaluated a perioperative strategy with combination chemotherapy and preoperative stereotactic radiation therapy (SBRT) to improve the R0 resection rate. Methods: This prospective, multicenter open label, single arm phase 2 clinical trial conducted among 5 member AGICC institutions enrolled pts with R-PDAC and BR-PDAC. Treatment included 3 cycles of gemcitabine (1000mg/m 2 ) and nab-paclitaxel (125 mg/m 2 ) (GEM/NAB) on days 1, 8 and 15 of a 28-day cycle prior to SBRT (33Gy: 6.6Gy daily x 5) followed by surgery and 3 cycles of adjuvant GEM/NAB. Accrual goal was 20 R-PDAC and 30 BR-PDAC pts selected by central radiology review. Primary objective was to estimate the R0 resection rate for each cohort. Secondary objectives included safety and tolerability of neoadjuvant treatment and OS. Results: Eighty-six pts signed consent and after radiologic screening, 20 R-PDAC patients and 29 BR-PDAC patients were found eligible to begin treatment. One R-PDAC and two BR-PDAC pts did not initiate therapy. 14 (70%) and 19 (66%) R-PDAC and BR-PDAC pts, respectively, completed all neoadjuvant chemotherapy.14 R-PDAC (70%) and 17 BR-PDAC (59%) pts completed SBRT. 11 R-PDAC pts (55%) and 11 (38%) BR-PDAC, underwent surgery. 8 R-PDAC pts (40%) had an R0 resection. One R-PDAC pt had a complete pathologic response (pCR). 8 BR-PDAC pts (28%) had an R0 resection. 19% (3/16) pts undergoing an R0 resection are alive (47-73+ mos). 16 pts (32%) had at least one grade ≥ 3 non-hematologic adverse event (AE); 25 patients (51%) had at least one grade ≥ 3 hematologic AE. 8 pts, 4 R-PDAC and 4 BR-PDAC were hospitalized prior to surgery. One pt (2%) died during NAT. There were no deaths due to surgery. Conclusions: R0 resection rates and survival in R-PDAC and BR-PDAC were low despite a perioperative approach of systemic therapy and SBRT. The lack of survival benefit of GEM/NAB as an adjuvant regimen, as well as SBRT pre-operatively (both shown in studies subsequent to this one) may explain the disappointing results. While an R0 resection for localized PDAC is recognized as essential, our results demonstrate that an R0 resection is not sufficient to cure the majority of PDAC pts who receive NAT with GEM/NAB + SBRT. Future NAT therapy trials should aim to markedly improve the pCR rates associated with R0 resection. Clinical trial information: NCT02723331.

Clinical